Funding profile · Oncology diagnostics

Known Medicine

One announced round of $7.2 million, no Form D on file with the SEC, no federal grant on record, and an acquisition 21 months later. The capital picture here is built almost entirely from press releases.

$7.2MSeed round announced Aug 25, 2021, company-reported
$150KY Combinator seed money, reported Aug 2020
0Form D filings found on SEC EDGAR
$0Federal grant dollars on record at NIH or NSF

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2020 Y Combinator, 2020 batch $150,000 Y Combinator Trade press
Aug 2021 Seed $7,200,000 Led by Caffeinated Capital; Khosla Ventures, Cota Capital, Kickstart, Forward VC, OATV, Y Combinator; angels Chris Gibson and Nish Bhat Company release
2021 to 2023 No further round announced None disclosed None named Not found
May 2023 Acquisition by Pathos AI Not disclosed Pathos AI Acquirer-stated

What the filings show

Known Medicine, Inc. · no Form D found

EDGAR company search
No matching companies for Known Medicine or Known Med, any form type
EDGAR full text search
Six documents contain the phrase, all unrelated filings by other registrants
Filer identifier
None. No CIK exists for the company
Announced capital covered
$0 of the $7.35 million reported across 2020 and 2021
Searched
Sep 23, 2026

Federal non-dilutive funding · none on record

NIH RePORTER
No project awarded to an organisation named Known Medicine
NSF awards
No award to the company. An automated name search returns 25 awards, all to universities and other firms whose names contain the word Medicine
SBIR and STTR
No award found under the company name
Searched
Sep 23, 2026

Reading the filings

  1. The absence is legal, not suspicious.A company that raises under Section 4(a)(2) rather than Regulation D files no Form D at all, and priced seed rounds are often done that way. The result for an outside reader is that there is no filed document anywhere confirming the $7.2 million, the share class, the pre-money valuation or the investor count. The figure rests on the company’s own August 2021 release, which trade press repeated.
  2. Every dollar is dilutive.NIH RePORTER and NSF return nothing for this company, and no SBIR award appears. That is unusual for a Utah diagnostics company running a 2,000 patient tissue study, and it means the seed round carried the full cost of the laboratory, the sample logistics and the clinical consortium.
  3. Twenty one months from round to exit.The seed closed in August 2021. The acquisition was announced on May 23, 2023. A $7.2 million seed at that burn profile does not usually last much beyond two years, so the timing is consistent with a company selling near the end of its runway rather than from a position of strength. No later financing was ever announced.
  4. The acquirer disclosed nothing and needed to disclose nothing.Pathos AI was private, had raised $40 million at the time, and folded Known Medicine in without a price. There is no 8-K, no S-1 disclosure and no Form D naming the transaction. Pathos has since raised a $365 million Series D at roughly $1.6 billion post-money and acquired Rain Oncology, a public company, where the terms were disclosed.
  5. The clinical record stopped when the money changed hands.The last update to NCT05338073 was posted on April 24, 2023, one month before the acquisition. The study is now listed as unknown status with no results. For an investor, that is the single most informative date on the page: the validation programme the seed round was raised to fund has produced no public output.

Commercial signals

Signal Detail Source type
Regulatory No FDA 510(k) and no premarket approval. The Known 3Dx test is recorded in the trial registry as an FDA regulated device that is not approved. Public record
Revenue None disclosed. No named paying pharmaceutical partner was ever announced. Not found
Clinical sites Mayo Clinic, Duke Cancer Institute and MD Anderson listed as collaborators on NCT05338073. The company separately said it worked with about 10 cancer research centres. Public record
Evidence No peer-reviewed validation of the platform. No posted trial results. No published accuracy figure. Not found
Headcount 13 at the end of 2021, per the company. No later figure published. Company-stated
Exit Acquired by Pathos AI, announced May 23, 2023, terms undisclosed. Acquirer-stated

What to watch

  • Any disclosure of the Known Medicine purchase price, most likely in a future Pathos AI registration statement.
  • Whether Pathos names the organoid platform in its own filings. Its 2026 platform page does not mention 3D cell culture.
  • Any update, completion or withdrawal of NCT05338073, dormant since April 2023.
  • Whether the seed investors disclose a mark on the position in any public fund reporting.

The Known Medicine story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Correlia Biosystems: Shared investor: Cota Capital. A UC Berkeley spinout that stopped waiting for proteins to drift toward an antibody and started pushing them there with an electric field
  • Harmonic Discovery: Shared investor: Caffeinated Capital. A New York company using machine learning to design kinase drugs that engage several targets on purpose while avoiding the ones that cause harm
  • Mecha Health: Shared investor: M Seed Fund. Four University College London researchers built a chest x-ray model that writes the whole report, published benchmarks saying it matches or beats radiologists, and
  • Anja Health: Shared investor: M Seed Fund. A private cord blood, cord tissue and placenta bank built on TikTok, grown to about 2,000 families and $1.5 million a year, and sold in 2026

Sources

  1. Public recordSEC EDGAR company search and full text search, no filer and no Form DSEC · Sep 23, 2026
  2. Public recordNIH RePORTER organisation search, no awards returnedNIH · Sep 23, 2026
  3. Public recordNSF award search, no award to the companyNSF · Sep 23, 2026
  4. Public recordClinicalTrials.gov NCT05338073Last update Apr 24, 2023
  5. CompanyKnown Medicine Raises $7.2 Million Seed Round to Advance Data First Approach to Organoid TechnologyBusiness Wire · Aug 25, 2021
  6. IndependentKnown Medicine Closes $7.2M Seed Funding RoundPrecision Medicine Online · Aug 25, 2021
  7. IndependentKnown Medicine Raises $7.2M in Seed FundingFinSMEs · Aug 26, 2021
  8. IndependentY Combinator startup grows mini-tumors to take the guesswork out of cancer treatmentsFierce Biotech · Aug 11, 2020
  9. IndependentRe-engineering drug development for Precision MedicineRyan Fukushima, Pathos, on Medium · May 23, 2023
  10. IndependentEric Lefkofsky’s Pathos AI acquires cancer drug companyCrain’s Chicago Business · Dec 14, 2023
  11. IndependentPathos AI Secures $365 Million in Series D FinancingBioUtah · May 15, 2025
  12. CompanyKnown Medicine post on joining PathosX · May 23, 2023

Compiled from SEC, NIH, NSF and ClinicalTrials.gov public records and published reports as of September 23, 2026. Form D notices report offerings under Regulation D; a company that raises outside Regulation D files none, so the absence of a filing is not evidence that no money moved. Healthcare Venture Capital Fund holds no position in Known Medicine. This page is not an offer to sell or a recommendation to buy any security.